On risk analysis of the use of Cannabinoids compounds as therapy in Dementia

Pereira, Eduardo; Fernandes, Rúben; Luís, Carla; Baylina, Pilar; BAYLINA MACHADO, PILAR

http://hdl.handle.net/10400.22/30059

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
ART_Pilar Baylina.pdf		4.19 MB	Adobe PDF	Download

Send Feedback

Authors

BAYLINA MACHADO, PILAR

Abstract(s)

Nowadays dementia pharmaceutical treatment has an unfavourable risk-benefit relation. New therapeutic approaches’ adoption is need due to the high prevalence of this condition. To evaluate the risk of using cannabinoids compounds as nonharmful therapeutic approach in dementia. A systematic literature review based on PRISMA was performed. PubMed and Clinical Trials database were used to collect articles between 2012 and 2022. Cochrane and Consort instruments were used to evaluate the methodology quality and report quality of adverse effects. Tetrahydrocannabinol and Nabilone were associated to a moderate effectiveness in the symptomatology related with Dementia and to favourable safety and tolerability profiles. Evidence obtained shows the importance of these two compounds as a new approach to dementia treatment.

Keywords

Cannabinoids Dementia Risk Safety Effectiveness

URI

http://hdl.handle.net/10400.22/30059

Citation

Baylina, P., Pereira, E., Fernandes, R., & Luís, C. (2022). On risk analysis of the use of Cannabinoids compounds as therapy in Dementia: A systematic literature review. International Healthcare Review (Online). https://doi.org/10.56226/75